Clinical Trials Logo

Clotting Disorder clinical trials

View clinical trials related to Clotting Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT06227819 Completed - Heart Failure Clinical Trials

BVA-200 vs BVA-100 Validation Study

Start date: May 23, 2023
Phase:
Study type: Observational

The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device. Data from this study may be pooled with data from studies with similar design conducted at other sites, for the purposes of an FDA medical device submission.

NCT ID: NCT05387577 Terminated - Transgenderism Clinical Trials

Coagulation and Fibrinolysis of Estradiol in Transwomen

Start date: December 7, 2021
Phase: Early Phase 1
Study type: Interventional

The specific aim for our study is to measure coagulation system activation and fibrinolysis following transdermal versus sublingual versus oral estradiol versus in transgender women. Hypothesis: Transdermal estradiol will result in less coagulation system activation and no effect on plasminogen activator inhibitor (PAI-1) or tissue-type plasminogen activator (t-PA). Oral estradiol will result in the most coagulation system activation and effect on PAI-1 and t-PA: Oral estradiol > sublingual estradiol > transdermal estradiol. A prospective crossover study will include ten subjects given estradiol 1 mg daily and instructed to take it orally, sublingually, or transdermal for 2 months with a 2-week washout period between routes of administration. Labs will be measured 7 times during the study.

NCT ID: NCT05237492 Completed - Drug Toxicity Clinical Trials

The Influence of Tramadol on Platelet Function

Start date: January 26, 2022
Phase: Phase 4
Study type: Interventional

The aim of this ex-vivo study is to quantify the effect of tramadol on platelet aggregation.

NCT ID: NCT04824118 Completed - Clinical trials for Venous Thromboembolism

Clotting Parameters After Medical Abortion

C-PLAN
Start date: March 26, 2021
Phase:
Study type: Observational

Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women. There is evidence that clotting parameters can take up to 6 weeks to return to normal for women who have had term deliveries, however there is an absence of information on time taken for clotting parameters to normalise following abortion. As such, existing guidelines are based solely on expert opinion and recommend durations of VTE prevention from as short as 7 days, up to 6 weeks following abortion. All women are assessed for risk of VTE, but data are needed to inform an evidence-based approach to prevention of VTE in these women. The findings from this pilot study have the potential to inform clinical guidance and possibly a larger study subsequently.

NCT ID: NCT03962400 Withdrawn - Clotting Disorder Clinical Trials

Reinforcement Learning for Warfarin Dosing

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

This is a clinical study designed to test the hypothesis that a computer model for dosing warfarin is superior to current clinical practice. Subjects will be randomized to two groups based on how warfarin dose is determined and followed for 6 months. The primary outcome is the percent of the time that the INR is maintained in the effective range.